Phio Pharmaceuticals Corp
$ 1.35
4.65%
04 Dec - close price
- Market Cap 15,787,100 USD
- Current Price $ 1.35
- High / Low $ 1.37 / 1.25
- Stock P/E N/A
- Book Value 2.10
- EPS -2.09
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.02 %
- 52 Week High 9.79
- 52 Week Low 0.97
About
Phio Pharmaceuticals Corp. is a biotechnology firm based in Marlborough, Massachusetts, focused on developing groundbreaking therapeutics that harness the power of the immune system to combat cancer. Utilizing its proprietary self-delivering RNA interference (RNAi) technology, the company aims to create transformative treatments that enhance efficacy while minimizing adverse effects. With a strong pipeline of innovative product candidates, Phio is well-positioned to play a significant role in the advancing landscape of cancer immunotherapy, underscoring its commitment to pioneering research and development in the biopharmaceutical sector.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-14 | 2025-05-07 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-22 |
| Reported EPS | -0.4374 | -0.45 | -0.9379 | -0.85 | -1.54 | -3.62 | -0.85 | -0.85 | -1.14 | -1.4747 | -3.1535 | -2.4 |
| Estimated EPS | None | -0.36 | None | -1.23 | -4.14 | -4.59 | -1.3 | -1.3 | -1.43 | None | None | -3.24 |
| Surprise | 0 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 0.45 | 0.45 | 0.29 | 0 | 0 | 0.84 |
| Surprise Percentage | None% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 34.6154% | 34.6154% | 20.2797% | None% | None% | 25.9259% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2023-10-11 07:30:00
Phio Pharmaceuticals announced new preclinical data for its INTASYL™ compound PH-894, demonstrating its ability to make melanoma cells more recognizable to immune cells and act as an antitumor cytotoxic agent. The data, to be presented at the AACR-NCI-EORTC International Conference, supports the compound's potential for treating solid tumor indications by reducing BRD4 expression and inducing apoptosis in cancer cells. PH-894 is a precision self-delivering RNAi therapy primarily focused on immuno-oncology.
